FPH1
Based on 1 publication(s) in Google Scholar
FPH1 (BRD6125) is a hepatocyte proliferation agent that promotes functional proliferation of primary human hepatocytes and improves hepatocyte proliferation and secretory phenotypes. FPH1 promotes hepatocyte differentiation and maturation of human mesenchymal stem cells, and induces transcriptional upregulation of adult liver xenobiotic metabolism enzymes, including CYP2D6, CYP3A4, CYP2C19, and MAO-A. FPH1-induced chemical maturation confers primaquine sensitivity and reduces P. yoelii-luc and P. falciparum infection. FPH1 can be used in research related to liver diseases, such as liver failure and Plasmodium infection.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度 : 99.89%
- CAS 番号: 708219-39-0
- 分子式: C16H15ClF2N2O3S
- 分子量:388.82
-
保管条件:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- プロトコル
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
MedChemExpress（MCE）の使用を引用している文献 FPH1
More
生物活性
製品説明
IC50 & Target
[1]|
CYP2D6 |
CYP3A4 |
CYP2C19 |
MAO-A |
体外実験
FPH1 (~15 µM; 48 h) can induce functional proliferation of primary human hepatocytes in a high-throughput screening platform[3].
FPH1 (20 µM; supplemented on days 1 and 5) induces proliferation of primary human hepatocytes, increasing the area of albumin-positive colonies by up to 6.6-fold and the number of hepatocytes by up to 10-fold, while maintaining liver-specific functions[3].
FPH1 (9 days) promotes the maturation of human iPS-derived hepatocyte-like cells toward a phenotype closer to adult hepatocytes, increasing CYP3A4 activity by 45-fold and inducing the expression of mature hepatocyte markers including ABCB11[3].
FPH1 combined with FH1 treatment of human pluripotent stem cell-derived hepatic progenitor cells upregulates the hepatocyte maturation markers ALB, A1AT, and CYP family members, promoting the maturation of human pluripotent stem cell-derived hepatic progenitor cells into functional hepatocyte-like cells[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Primary human hepatocytes on growth-arrested J2-3T3 fibroblast feeder layer
-
Concentration:20 µM
-
Incubation Time:days 1 and 5
-
Result:Increased Ki67 staining co-localized with Hoechst and human albumin stains.
Increased albumin-positive colony area up to 6.6-fold.
Increased hepatocyte number up to 10-fold.
Maintained normal hepatocyte morphology, stable urea synthesis and albumin secretion, active MRP2 transport, and uncompromised CYP450 activity.
Showed no significant differences in gene expression profiling between FPH1-treated and untreated cells.
化学情報
-
CAS 番号 708219-39-0
-
性状 Solid
-
分子量 388.82
-
分子式 C16H15ClF2N2O3S
-
Color White to off-white
-
SMILES
O=C(NC1=C(F)C=CC=C1F)CN(C2=CC(Cl)=CC=C2C)S(=O)(C)=O
-
別名
BRD6125
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
溶剤 & 溶解度
体外:
DMSO : ≥ 250 mg/mL (642.97 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
体内:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.5 mg/mL (6.43 mM); Clear solution; Need ultrasonic
This protocol yields a clear solution of 2.5 mg/mL.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
純度とドキュメンテーション
-
データシート (283 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
取扱説明書 (2659 KB)
参考文献
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.5719 mL | 12.8594 mL | 25.7188 mL | 64.2971 mL |
| 5 mM | 0.5144 mL | 2.5719 mL | 5.1438 mL | 12.8594 mL | |
| 10 mM | 0.2572 mL | 1.2859 mL | 2.5719 mL | 6.4297 mL | |
| 15 mM | 0.1715 mL | 0.8573 mL | 1.7146 mL | 4.2865 mL | |
| 20 mM | 0.1286 mL | 0.6430 mL | 1.2859 mL | 3.2149 mL | |
| 25 mM | 0.1029 mL | 0.5144 mL | 1.0288 mL | 2.5719 mL | |
| 30 mM | 0.0857 mL | 0.4286 mL | 0.8573 mL | 2.1432 mL | |
| 40 mM | 0.0643 mL | 0.3215 mL | 0.6430 mL | 1.6074 mL | |
| 50 mM | 0.0514 mL | 0.2572 mL | 0.5144 mL | 1.2859 mL | |
| 60 mM | 0.0429 mL | 0.2143 mL | 0.4286 mL | 1.0716 mL | |
| 80 mM | 0.0321 mL | 0.1607 mL | 0.3215 mL | 0.8037 mL | |
| 100 mM | 0.0257 mL | 0.1286 mL | 0.2572 mL | 0.6430 mL |
FPH1 関連分類
HY-100590 関連分類
Powered by Bioz